BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’

BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is most likely to claim the regulatory accelerator.